Table 4 RYGB versus sleeve gastrectomy outcomes comparison.

From: Comparison of bariatric surgery and community weight management for idiopathic intracranial hypertension in a multicenter retrospective cohort study

Outcome

Follow-up duration

RYGB

Sleeve gastrectomy

Risk difference

Risk ratio

95% confidence interval

P-value

Papilledema

3 months

5.03%

5.03%

0

1

0.426–2.35

0.999

6 months

5.03%

5.03%

0

1

0.426–2.35

0.999

12 months

5.03%

5.03%

0

1

0.426–2.35

0.999

24 months

5.03%

5.53%

− 0.50%

0.909

0.395–2.092

0.8226

Increased ICP

3 months

5.03%

0

5.03%

N/A

N/A

0.0014

6 months

5.03%

5.03%

0

1

0.426–2.35

0.999

12 months

5.03%

5.03%

0

1

0.426–2.35

0.999

24 months

5.03%

5.03%

0

1

0.426–2.35

0.999

Headache

3 months

31.16%

33.67%

− 2.51%

0.925

0.697–1.229

0.5923

6 months

41.21%

34.67%

6.53%

1.188

0.923–1.53

0.1793

12 months

44.22%

41.21%

3.02%

1.073

0.855–1.348

0.5432

24 months

50.25%

45.73%

4.52%

1.099

0.895–1.349

0.3665

Optic atrophy

3 months

5.03%

0

5.03%

N/A

N/A

0.0014

6 months

5.03%

5.03%

0

1

0.426–2.35

0.999

12 months

5.03%

5.03%

0

1

0.426–2.35

0.999

24 months

5.03%

5.03%

0

1

0.426–2.35

0.999

Blindness

3 months

5.03%

5.03%

0

1

0.426–2.35

0.999

6 months

5.03%

5.03%

0

1

0.426–2.35

0.999

12 months

5.03%

5.03%

0

1

0.426–2.35

0.999

24 months

5.03%

5.03%

0

1

0.426–2.35

0.999

Pulsatile tinnitus

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

5.03%

0

5.03%

N/A

N/A

0.0014

24 months

5.03%

0

5.03%

N/A

N/A

0.0014

Abducent nerve palsy

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

0

0

N/A

N/A

N/A

N/A

24 months

5.03%

5.03%

0

1

0.426–2.35

0.999

Diplopia

3months

5.03%

5.03%

0

1

0.426–2.35

0.999

6 months

5.03%

5.03%

0

1

0.426–2.35

0.999

12 months

5.03%

5.03%

0

1

0.426–2.35

0.999

24 months

5.03%

5.03%

0

1

0.426–2.35

0.999

Refractory IIH

3 months

30.65%

31.66%

− 1.01%

0.968

0.723–1.297

0.8286

6 months

40.20%

34.17%

6.03%

1.176

0.91–1.521

0.2133

12 months

42.71%

40.70%

2.01%

1.049

0.832–1.324

0.6843

24 months

48.24%

45.23%

3.02%

1.067

0.865–1.316

0.5466

Visual discomfort and visual field defects

3 months

0

5.03%

− 5.03%

N/A

N/A

0.0014

6 months

5.03%

5.03%

0.00%

1

0.426–2.35

0.999

12 months

5.03%

5.03%

0.00%

1

0.426–2.35

0.999

24 months

5.03%

5.03%

0.00%

1

0.426–2.35

0.999

CSF leak

3 months

0

5.03%

− 5.03%

N/A

N/A

0.0014

6 months

0

5.03%

− 5.03%

N/A

N/A

0.0014

12 months

0

5.03%

− 5.03%

N/A

N/A

0.0014

24 months

0

5.03%

− 5.03%

N/A

N/A

0.0014

Therapeutic spinal puncture rate

3 months

0

5.03%

− 5.03%

N/A

N/A

0.0014

6 months

0

0.00%

− 

N/A

N/A

N/A

12 months

0

5.03%

− 5.03%

N/A

N/A

0.0014

24 months

5.03%

5.03%

0.00%

1

0.426–2.35

0.999

CSF shunting rate

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

0

0

N/A

N/A

N/A

N/A

24 months

0

0

N/A

N/A

N/A

N/A

ONSF rate

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

0

0

N/A

N/A

N/A

N/A

24 months

0

0

N/A

N/A

N/A

N/A

Acetazolamide use

3 months

15.08%

12.56%

2.51%

1.2

0.733–1.965

0.4677

6 months

17.09%

10.05%

7.04%

1.7

1.015–2.849

0.0404

12 months

20.10%

13.57%

6.53%

1.481

0.948–2.316

0.0816

24 months

23.12%

14.07%

9.05%

1.643

1.072–2.517

0.0204

Back to article page